Clock

Figures converted from Israeli shekels (₪) at historical FX rates — see data/company.json.fx_rates. NICE reports its financial results in US dollars, so revenue, EPS, and free cash flow are unchanged; only the shekel share-price levels and shekel-converted analyst targets are shown in dollars (share levels at ₪→$ 0.32641, applied uniformly so the −40.6% drawdown is preserved). Ratios, margins, and multiples are unitless and unchanged.

Clock — the mechanism, the timing, the instruments

The nearest dated catalyst is the Q2 2026 report on 5 August 2026, which tests a deliberately soft 5.5% revenue guide; consensus models the growth trough at that print and a reacceleration through FY2027. The two prior guide-driven drawdowns round-tripped inside four months, but this one is roughly double their depth. The sell side has not capitulated — zero sell ratings, price targets averaging ~35% above spot. Listed NASDAQ options run out to a January 2028 LEAP; near-term implied volatility sits at ~58–62%, elevated.

NICE reports results in US dollars but its shares trade in shekels on the Tel Aviv Stock Exchange, with a NASDAQ ADR twin (one ADR per ordinary share). Below, price levels, market value, and analyst targets are shown in $ (shekel closes converted at ₪→$ 0.32641; ADR targets are natively in dollars); revenue, EPS, and free cash flow are in $ as the company reports them. The companion page shows the native shekel levels.

The re-rating mechanism — five dated levers, one imminent

What would close the gap is not "sentiment." It is a specific set of printed events, each with a calendar. The dislocation itself — a 40.6% peak-to-trough fall whose defining leg was the 18.8% single-session drop on the 6-May Q1 report — is anatomized in the Dislocation tab; this tab is about what reverses it and when.

1. The Q2 2026 print against a low bar — 5 August 2026 (imminent). Management guided Q2 non-GAAP revenue to $761–771 million, "representing 5.5% year over year growth at the midpoint" [1] — a deliberate step down from the 9.8% just reported, set low after pricing concessions pulled revenue into a Q2 "phasing" hole. Consensus has settled at $766.4 million and $2.64 of EPS for the quarter (CapIQ / yfinance, 15–16 analysts). The mechanism here is guidance resetting against a bar the company itself lowered: a Q2 that meets or clears the soft guide, with cloud net-revenue-retention no longer sliding, removes the specific fear that repriced the stock. It is the single most concrete near-term event, roughly two weeks out.

2. Cloud-growth reacceleration showing up in the printed line — H2 2026 into 2027. Consensus does not expect the deceleration to continue: revenue-growth troughs at the Q2 +5.5% and reaccelerates to +8.7% at Q3 (reported ~November 2026) and +9.7% for FY2027. The engine is AI ARR, which grew 66% year over year to $345 million but is still only ~14% of cloud — not yet large enough to offset the seat compression showing in retention. The catalyst is the crossover printing: cloud net revenue retention, reported at 107% and falling, stabilizing or turning up [2]. Window: two to four quarters of prints.

3. EPS growth returning against an easy compare — FY2027. FY2026 is an earnings-down year — consensus EPS of $11.09 is 9.8% below FY2025's ~$12.30 as the AI transition absorbs investment. Consensus then has FY2027 EPS at $12.63, up 13.9% and back above the 2025 level. The YoY compares turn favourable from the Q1 2027 print (~May 2027); that is when the growth-stock screen sees a re-accelerating earnings line again.

4. The buyback shrinking the denominator — continuous. NICE repurchased a record $253 million of stock in Q1 2026, about 3.5% of its market capitalization, exited the quarter with $745 million of authorization remaining, and is "committed to our share repurchases exceeding 50% of our free cash flow this year," cutting shares ~5% year over year [3]. This is mechanical and does not wait for a catalyst; its pace and coverage are quantified in Self-Help.

5. The Actimize divestiture — a live process, no fixed close. NICE put its Actimize financial-crime unit up for sale at a $1.5–2 billion tag in November 2025; by early May 2026 "five bidders advance in Nice's $2.5 billion Actimize sale process," with the floor reported near ~$2.5 billion [4]. A completed sale would crystallize a sum-of-parts discount and hand more capital to the buyback. The caveat is real: the corpus documents an active auction and non-binding bids, not a signed deal or a closing date, so this lever carries execution and timing risk the others do not.

Sources: Q2 and full-year guidance, Q1 2026 press release [5]; Q1 2026 call [6]; Actimize process, news digest [7]; consensus horizons from CapIQ / yfinance estimates (data/estimates/analyst_estimates.json).

Base rates — NICE's own history of guide-driven drawdowns

The framework asks for prior drawdown episodes of comparable depth from this name's own history — how deep, how long to trough, how long to round-trip. A limitation binds first: the run's price feed is a six-month, web-sourced daily history (23 January – 21 July 2026), so a multi-year, price-measured base-rate table cannot be built from the run's own price data. What the corpus does give is a repeated, dated pattern: a beat overwhelmed by a soft cloud/margin guide, sold off hard in a single session.

• February 2025. NICE "beats Q4 estimates but shares plunge on weak 2025 outlook" — a cautious FY2025 guide after 25% FY2024 cloud growth [8]. Depth not quantified in the corpus.
• November 2025. "Nice shares plummet as AI growth can't offset weak guidance" — a roughly 20% single-quarter plunge on the soft 2026 profitability outlook, contemporaneously framed as "NICE's 20% Plunge: A Catalyst-Driven Mispricing or Justified Discount?" [9].
• May 2026. The current episode: an 18.8% single-session drop, 40.6% peak-to-trough — the deepest of the three, and roughly double the November precedent.

The round-trip base rate is where the price feed helps. NICE traded at $114.0 on 23 January 2026 and made a marginal high of $135.2 on 5 March 2026 — meaning the ~20% November 2025 plunge had fully round-tripped and printed a higher high in roughly four months. The February 2025 drawdown had likewise been recovered by then. On the two occasions the run's evidence can bracket, a guide-driven drawdown was recovered inside a year, and the shallower November episode inside a single quarter. The current episode is deeper than either, so applying their four-month round-trip to a 40.6% fall is not warranted — the base rate says these drawdowns have reversed, not that they reverse this fast at twice the depth.

Sources: prior-episode magnitudes and framing from the news digest [10]; $114.0, $135.2, $80.4, $95.2 levels and the −40.6% depth from the run's daily price feed (data/prices/daily.json) and fit_features.capitulation_gauge.drawdown.

The current episode's recovery-so-far is visible in the feed: from the $80.4 trough on 19 June, the stock is back to $95.2 — up 18.5% off the low in about five weeks, still 29.6% below the March peak.

Source: daily close, TASE, converted to $ (data/prices/daily.json); trough $80.4 (19 Jun 2026) and current $95.2 (21 Jul 2026) per fit_features.capitulation_gauge.drawdown.

The 18-month test

Given the mechanism and the base rates, re-recognition within ~18–24 months is a reasonable expectation, contingent on one thing: the cloud-growth and net-revenue-retention line stabilizing in printed quarters. Three facts support it — consensus itself models the growth trough at the imminent Q2 print with reacceleration through FY2027; the two prior guide-driven drawdowns round-tripped within four to twelve months; and the buyback shrinks the denominator every quarter without waiting for a catalyst. The path does not obviously require years of cycle repair. What would falsify that read is concrete and belongs to the Damage Math tab's ledger: if agentic AI is structurally displacing the human seats NICE bills against, cloud growth keeps decelerating below the guided 13%–15% and NRR keeps falling, no printed quarter reaccelerates, and the 18-month window becomes a multi-year AI-transition repair instead.

What consensus expects, and when

Two readings matter here: where the sell side is positioned, and when it expects the recovery to print.

The sell side has not capitulated. Of 16 covering analysts, the current split is 2 strong-buy, 7 buy, 7 hold, and 0 sell; three months ago it was 4 strong-buy, 5 buy, 7 hold, 0 sell — the top of the rating stack softened, but no analyst has moved to sell through the entire 40.6% drawdown. The price-target range tells the same story: on the NASDAQ ADR the mean target is ~$128 and the low target is $100, both above the ~$95 ADR spot — the entire published target range sits at or above the current price.

Source: analyst price targets and recommendation counts, CapIQ / yfinance as of 23 Jul 2026 (data/estimates/analyst_estimates.json); spot is the ₪291.8 close converted at 0.32641 (data/company.json.fx_rates, 2026-07-23).

The recovery is expected to print, but not immediately. Consensus has revenue growth troughing at the Q2 +5.5% and reaccelerating from Q3; EPS, by contrast, is down ~12% year over year in both Q2 and Q3 2026 and does not turn positive until FY2027 (+13.9%). A re-rating usually needs a printed quarter, and the candidate is not the very next one: the earliest quarter consensus itself models a re-accelerating earnings line is Q1 FY2027 (~May 2027), while the revenue line reaccelerates a step earlier at Q3 2026 (~November 2026). Estimate revisions are not cutting into that: FY2026 EPS has been revised up by 16 of 16 analysts over the last 30 days and nudged from $10.95 to $11.09 over 90 days.

Source: consensus revenue and EPS estimates, CapIQ / yfinance, 15–16 analysts (data/estimates/analyst_estimates.json, earnings_estimate & revenue_estimate).

The free-cash-flow path consensus models runs the same shape: a dip to $589.8 million in FY2026 from FY2025's $648.6 million, then reacceleration to $694.8 million (FY2027), $767.4 million (FY2028), and $829.1 million (FY2029) (CapIQ consensus; the yield this implies is in the Yield tab).

Instrument facts

These are stated as facts, not suggestions. NICE's NASDAQ ADRs (traded in US dollars, one ADR per ordinary share) carry listed options with long-dated expiries. As of 22 July 2026, the available expirations run 21 August 2026, 18 September 2026, 20 November 2026, 15 January 2027, 19 February 2027, and a 21 January 2028 LEAP — so contracts more than 12 months out (indeed ~18 months) exist. Open interest is present but modest against a mega-cap: near-the-money contracts show open interest in the hundreds to low thousands (for example a near-money put with roughly 2,053 contracts open).

The current implied-volatility level, from a dated source, is elevated. On 22 July 2026 near-the-money August-2026 contracts carried implied volatility of roughly 58%–62% (a ~$90 call near 62%, a ~$95 put near 58%) — into the "elevated" band by the framework's reference lines (up to ~50–55 acceptable, 60–70 elevated). That August contract spans the 5 August earnings date, so it embeds event premium. For context, the same instrument showed implied volatility near 45% in mid-April 2026, before the dislocation — the vol premium has risen with the drawdown. These readings are from a delayed public options feed (Investing.com), dated and citable but not real-time exchange data; strikes and expiries are reported here as facts about the instrument, not as anything to act on.

Because long-dated options do exist on this name, the framework's watchlist-routing consequence — the rule that sends names lacking long-dated instruments off the book — does not bind here as a matter of instrument availability.